Brokers Offer Predictions for VRCA Q4 Earnings

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) – Research analysts at Brookline Capital Management issued their Q4 2025 EPS estimates for shares of Verrica Pharmaceuticals in a research report issued on Tuesday, March 11th. Brookline Capital Management analyst K. Dolliver expects that the company will post earnings per share of ($0.03) for the quarter. The consensus estimate for Verrica Pharmaceuticals’ current full-year earnings is ($1.46) per share.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its earnings results on Tuesday, March 11th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.01. The company had revenue of $0.34 million for the quarter, compared to analyst estimates of $1.30 million. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%.

Separately, Needham & Company LLC restated a “hold” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Verrica Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $9.50.

Verrica Pharmaceuticals Stock Performance

Shares of NASDAQ VRCA opened at $0.54 on Friday. The firm has a market capitalization of $24.50 million, a P/E ratio of -0.29 and a beta of 1.44. Verrica Pharmaceuticals has a one year low of $0.54 and a one year high of $11.41. The company’s fifty day moving average is $0.67 and its two-hundred day moving average is $1.08.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Caligan Partners LP acquired a new position in shares of Verrica Pharmaceuticals during the 4th quarter worth $5,201,000. Boothbay Fund Management LLC acquired a new position in shares of Verrica Pharmaceuticals during the 4th quarter worth $1,811,000. State Street Corp raised its stake in shares of Verrica Pharmaceuticals by 13.5% during the 3rd quarter. State Street Corp now owns 512,821 shares of the company’s stock worth $744,000 after buying an additional 61,041 shares during the last quarter. Geode Capital Management LLC raised its stake in Verrica Pharmaceuticals by 4.8% in the 4th quarter. Geode Capital Management LLC now owns 477,269 shares of the company’s stock valued at $334,000 after purchasing an additional 21,789 shares during the last quarter. Finally, Sovran Advisors LLC acquired a new position in Verrica Pharmaceuticals in the 4th quarter valued at about $267,000. Institutional investors and hedge funds own 42.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.